BRUSSELS (Reuters) - The European Commission said on Friday it had reached a deal with British pharmaceutical firm AstraZeneca for the purchase of at least 300 million doses of its potential COVID-19 vaccine.
The EU's executive arm, which is negotiating on behalf of the 27 EU states, said the deal included an option to purchase 100 million additional doses should the vaccine prove safe and effective.
The agreement marks the EU's first advance purchase deal for a potential vaccine against the new coronavirus.
"Today, after weeks of negotiations, we have the first EU Advance Purchase Agreement for a vaccine candidate," EU health commissioner Stella Kyriakides said in a statement.
It follows an initial deal with AstraZeneca reached in June by Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy and the Netherlands to secure vaccine doses for all member states.
The Commission did not disclose the terms of the new deal nor say whether conditions agreed earlier had been modified.
(Reporting by Francesco Guarascio; editing by Jan Harvey and Jason Neely)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)